Idit Sagiv-Barfi

7PUBLICATIONS
55CO-AUTHORS
Molecular targetsSolid tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 31, 2023
Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors.

Caitlyn L Miller, Idit Sagiv-Barfi, Patrick Neuhöfer

|May 27, 2022
Intratumoral immunotherapy relies on B and T cell collaboration.

Idit Sagiv-Barfi, Debra K Czerwinski, Tanaya Shree

|Feb 09, 2022
Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer.

Wan Xing Hong, Idit Sagiv-Barfi, Debra K Czerwinski

|Sep 21, 2021
Supporting the Next Generation of Scientists to Lead Cancer Immunology Research.

Elise Alspach, Ryan D Chow, Shadmehr Demehri

|Apr 21, 2021
An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory.

Ole A W Haabeth, Julian J K Lohmeyer, Adrienne Sallets

Pageof 2